Omada Health shares jumped after the company made its public-market debut, propelled by Americans’ renewed focus on how ...

Omada is trading publicly after 14 years of providing support to patients with weight-related chronic illnesses. Leadership sees the current moment as the perfect time for an IPO, as GLP-1 drugs such ...

GLP-1 drugs alter taste perception… and commonly disrupt the perception of sweetness, bitterness, fatty foods and even ...

The Indianapolis-based drugmaker sees orforglipron as a potential global breakthrough treatment for weight loss and other ...

A new study has found a significant association between the use of GLP-1s such as Ozempic and Wegovy with a higher risk of developing a serious eye condition in patients with diabetes. Here are four t ...

The mother-of-two was surprised to find out that she was pregnant with another child after struggling to conceive in the past ...

Mr. Funk was the managing editor of Pleroma Media, and worked as a breaking news reporter at The Messenger after spending 25 ...

Omada Health went public on the Nasdaq Friday, marking the second digital health company to do so after a post-pandemic ...

A potentially blinding condition is a very rare side effect of the GLP-1 receptor agonist semaglutide (Ozempic, Wegovy, ...

Patients with diabetes who utilize GLP-1 RAs for 6 months or longer are twice as likely to develop neovascular age-related macular degeneration.

Ozempic teeth” is a term used to describe the unexpected dental side effects of Ozempic, including bad breath, gum irritation ...

On May 21, 2025, the Connecticut Office of the Attorney General released a statement and sent letters to Connecticut weight ...